Pfizer (NYSE:PFE) Issues FY 2025 Earnings Guidance

Pfizer (NYSE:PFE - Get Free Report) updated its FY 2025 earnings guidance on Tuesday. The company provided EPS guidance of 2.800-3.000 for the period, compared to the consensus EPS estimate of 2.880. The company issued revenue guidance of $61.0 billion-$64.0 billion, compared to the consensus revenue estimate of $63.3 billion. Pfizer also updated its FY24 guidance to $2.75-2.95 EPS.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. Wolfe Research initiated coverage on Pfizer in a research report on Friday, November 15th. They issued an "underperform" rating and a $25.00 target price on the stock. Bank of America restated a "neutral" rating and issued a $29.00 price target on shares of Pfizer in a research report on Tuesday, December 10th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $45.00 price target on shares of Pfizer in a research note on Wednesday, October 23rd. Guggenheim lowered their price objective on shares of Pfizer from $35.00 to $33.00 and set a "buy" rating for the company in a research report on Wednesday, December 11th. Finally, Evercore ISI upgraded shares of Pfizer to a "strong-buy" rating in a research report on Wednesday, October 30th. One analyst has rated the stock with a sell rating, nine have issued a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, Pfizer currently has a consensus rating of "Hold" and an average target price of $32.15.

Pfizer Trading Up 4.6 %

Shares of PFE stock traded up $1.17 on Tuesday, reaching $26.42. 71,239,705 shares of the company's stock were exchanged, compared to its average volume of 38,635,492. The company's fifty day simple moving average is $27.09 and its 200 day simple moving average is $28.25. The stock has a market capitalization of $149.72 billion, a PE ratio of 35.49, a P/E/G ratio of 0.63 and a beta of 0.65. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer has a 52 week low of $24.48 and a 52 week high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.64 by $0.42. The firm had revenue of $17.70 billion during the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business's revenue was up 31.2% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.17) earnings per share. As a group, analysts forecast that Pfizer will post 2.95 EPS for the current year.

Pfizer Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.51%. The ex-dividend date of this dividend is Friday, January 24th. This is an increase from Pfizer's previous quarterly dividend of $0.42. Pfizer's payout ratio is currently 227.03%.

Insider Activity at Pfizer

In other news, Director Scott Gottlieb acquired 1,000 shares of the firm's stock in a transaction that occurred on Wednesday, October 30th. The stock was purchased at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the acquisition, the director now directly owns 10,000 shares of the company's stock, valued at $282,400. The trade was a 11.11 % increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.06% of the stock is owned by company insiders.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.